An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Adocia, a clinical-stage biopharmaceutical company based in Lyon, France, has confirmed its eligibility for the PEA-PME stock savings tax regime. This eligibility, effective from March 6, 2014, is based on the company's market capitalization being under one billion euros, having less than 5,000 employees, and an annual turnover below 1.5 billion euros. Adocia specializes in developing therapeutic solutions for diabetes and metabolic diseases and holds over 25 patent families.
Positive
Adocia qualifies for the PEA-PME stock savings tax regime, potentially attracting more investors.
The company holds more than 25 patent families, indicating a strong intellectual property portfolio.
Negative
None.
LYON, France--(BUSINESS WIRE)--
Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutic solutions for the treatment of diabetes and other metabolic diseases, confirms its eligibility for the “PEA – PME” stock savings tax regime, which decree has been published in the French Journal Officiel on March 4, 2014 (Decree n ° 2014-283), and which entered into force on March 6, 2014.
To be eligible for the “PEA – PME”, the shares must have been issued by a company whose market capitalization is below one billion euros, which has less than 5,000 employees, and an annual turnover not exceeding 1.5 billion euros or a total balance sheet less than 2 billion euros.
Adocia meets all of these conditions.
About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on three proprietary technology platforms:
1) The BioChaperone® technology for the development of new generation insulins and products combining insulins with other classes of hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation with a first application in pancreatic cells transplantation for patients with "brittle" diabetes.
Adocia holds more than 25 patent families.
Based in Lyon, the company has approximately 115 employees. Adocia is listed on the EuronextTMParis market (Euronext: ADOC; ISIN: FR0011184241).
Disclaimer
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the “Risk Factors” section of the universal registration document that was filed with the French Autorité des marchés financiers on April 21, 2022 (a copy of which is available at www.adocia.com), in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic context, the financial markets and the markets in which Adocia operates.
The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.
This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia’s shares in any jurisdiction.
Ulysse Communication
Adocia Press and Investors Relations
Pierre-Louis Germain Margaux Puech Pays d’Alissac
Bruno Arabian adocia@ulysse-communication.com
+33 (0)6 64 79 97 51
Source: ADOCIA
FAQ
What does Adocia's eligibility for the PEA-PME tax regime mean for investors?
Adocia's eligibility for the PEA-PME tax regime means that investors can benefit from tax advantages, potentially increasing interest in the company.
What are the criteria for PEA-PME eligibility that Adocia meets?
Adocia meets the PEA-PME eligibility criteria of having a market capitalization below one billion euros, fewer than 5,000 employees, and an annual turnover not exceeding 1.5 billion euros.
When did Adocia's eligibility for the PEA-PME regime come into effect?
Adocia's eligibility for the PEA-PME regime became effective on March 6, 2014.
What is Adocia's focus in biotechnology?
Adocia focuses on the discovery and development of therapeutic solutions primarily for diabetes and obesity.
How many patents does Adocia hold?
Adocia holds more than 25 patent families, demonstrating a significant intellectual property presence.
